Ally Bridge Group

Ally Bridge Group is a global healthcare-focused investment firm specializing in life sciences, with offices in New York and Hong Kong. Founded in 2013 by Frank Yu, the firm manages over US$2 billion in assets across private and public equity investments. Ally Bridge Group focuses on high-impact life science innovation, investing in areas such as biopharmaceuticals, medical devices, and healthcare IT. The firm has been involved in significant transactions, including leading the US$3.3 billion take-private of Wuxi Pharmatech in 2015 and a US$300 million Series C financing for GRAIL in 2018. Their portfolio includes companies like VitalConnect, WuXi AppTec, and WuXi Biologics. Ally Bridge Group aims to generate superior risk-adjusted returns for investors while addressing unmet medical needs, blending deep scientific and clinical research with proven M&A and capital markets expertise. They invest across the global healthcare industry through private equity and public equity strategies.

Focus on innovative life science technologies, Preference for companies with strong scientific and clinical foundations, Interest in both private and public equity investments, Willingness to engage in high-impact transactions, Alignment with the firm's global healthcare focus